Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
This patent covers several new isoquinolinamine compounds and their pharmaceutical composition and method for producing an anti-tumor effect. Studies show that isoquinolinamine compounds have potent anti-tumor properties in several cancer cell lines, such as breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma. This class of isoquinolinamine compounds significantly inhibited the growth of paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells and tumor growth in an in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.
Rexahn has been awarded patents for isoquinolinamine compounds in the United States, Mexico, China and now Europe.
"This patent coverage in Europe supports Rexahn's goal of accelerated development of this exciting new class of anti-cancer compounds," said Rick Soni, President of Rexahn.
Study shows AI can predict prognosis in triple-negative breast cancer